Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 420

1.

How conclusive is the CONCLUDE trial?

Del Prato S.

Diabetologia. 2020 Jan 16. doi: 10.1007/s00125-020-05086-8. [Epub ahead of print]

PMID:
31950229
2.

Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy.

Lapolla A, Genovese S, Giorgino F, Disoteo O, Sartore G, Bartezaghi M, Del Prato S.

Curr Med Res Opin. 2020 Jan 9:1-8. doi: 10.1080/03007995.2019.1707649. [Epub ahead of print]

PMID:
31868033
3.

Reinterpreting Cardiorenal Protection of Renal Sodium-Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming.

Avogaro A, Fadini GP, Del Prato S.

Diabetes Care. 2019 Dec 16. pii: dc191410. doi: 10.2337/dc19-1410. [Epub ahead of print]

PMID:
31843950
4.

Effects of treatment with metformin and/or sitagliptin on beta-cell function and insulin resistance in prediabetic women with previous gestational diabetes.

Daniele G, Tura A, Dardano A, Bertolotto A, Bianchi C, Giusti L, Kurumthodathu JJ, Del Prato S.

Diabetes Obes Metab. 2019 Dec 4. doi: 10.1111/dom.13940. [Epub ahead of print]

PMID:
31802616
5.

Altered Visual Plasticity in Morbidly Obese Subjects.

Lunghi C, Daniele G, Binda P, Dardano A, Ceccarini G, Santini F, Del Prato S, Morrone MC.

iScience. 2019 Dec 20;22:206-213. doi: 10.1016/j.isci.2019.11.027. Epub 2019 Nov 16.

6.

Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study.

Garofolo M, Gualdani E, Giannarelli R, Aragona M, Campi F, Lucchesi D, Daniele G, Miccoli R, Francesconi P, Del Prato S, Penno G.

Cardiovasc Diabetol. 2019 Nov 16;18(1):159. doi: 10.1186/s12933-019-0961-7.

7.

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.

Ray KK, Del Prato S, Müller-Wieland D, Cariou B, Colhoun HM, Tinahones FJ, Domenger C, Letierce A, Mandel J, Samuel R, Bujas-Bobanovic M, Leiter LA.

Cardiovasc Diabetol. 2019 Nov 9;18(1):149. doi: 10.1186/s12933-019-0951-9.

8.

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.

Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group.

Lancet. 2019 Oct 26;394(10208):1519-1529. doi: 10.1016/S0140-6736(19)32131-2. Epub 2019 Sep 18.

PMID:
31542292
9.

Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.

Blonde L, Rosenstock J, Del Prato S, Henry R, Shehadeh N, Frias J, Niemoeller E, Souhami E, Ji C, Aroda VR.

Diabetes Care. 2019 Nov;42(11):2108-2116. doi: 10.2337/dc19-1357. Epub 2019 Sep 17.

PMID:
31530665
10.

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes.

Bailey CJ, Del Prato S, Wei C, Reyner D, Saraiva G.

Diabetes Obes Metab. 2019 Nov;21(11):2564-2569. doi: 10.1111/dom.13841. Epub 2019 Aug 26.

11.

Heterogeneity of diabetes: heralding the era of precision medicine.

Del Prato S.

Lancet Diabetes Endocrinol. 2019 Sep;7(9):659-661. doi: 10.1016/S2213-8587(19)30218-9. Epub 2019 Jul 22. No abstract available.

PMID:
31345775
12.

A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM.

Matthews DR, Paldánius PM, Stumvoll M, Han J, Bader G, Chiang Y, Proot P, Del Prato S.

Diabetes Obes Metab. 2019 Oct;21(10):2240-2247. doi: 10.1111/dom.13800. Epub 2019 Jun 30.

13.

Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care.

Vaccaro O, Lucisano G, Masulli M, Bonora E, Del Prato S, Rivellese AA, Giorda CB, Mocarelli P, Squatrito S, Maggioni AP, Riccardi G, Nicolucci A; TOSCA.IT Investigators.

J Clin Endocrinol Metab. 2019 Aug 1;104(8):3296-3302. doi: 10.1210/jc.2019-00361.

PMID:
31058962
14.

Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome.

Avogaro A, Bonora E, Consoli A, Del Prato S, Genovese S, Giorgino F.

Diab Vasc Dis Res. 2019 Sep;16(5):399-414. doi: 10.1177/1479164119845612. Epub 2019 May 2. Review.

PMID:
31044622
15.

The role of adipokines in the pathogenesis of gestational diabetes mellitus.

de Gennaro G, Palla G, Battini L, Simoncini T, Del Prato S, Bertolotto A, Bianchi C.

Gynecol Endocrinol. 2019 Sep;35(9):737-751. doi: 10.1080/09513590.2019.1597346. Epub 2019 Apr 16. Review.

PMID:
30990092
16.

Exenatide modulates visual cortex responses.

Binda P, Eldor R, Huerta C, Adams J, Lancaster J, Fox P, Del Prato S, DeFronzo R, Abdul-Ghani M, Daniele G.

Diabetes Metab Res Rev. 2019 Sep;35(6):e3167. doi: 10.1002/dmrr.3167. Epub 2019 May 6.

17.

Early vs. standard screening and treatment of gestational diabetes in high-risk women - An attempt to determine relative advantages and disadvantages.

Bianchi C, de Gennaro G, Romano M, Battini L, Aragona M, Corfini M, Del Prato S, Bertolotto A.

Nutr Metab Cardiovasc Dis. 2019 Jun;29(6):598-603. doi: 10.1016/j.numecd.2019.02.007. Epub 2019 Mar 1.

PMID:
30954416
18.

The use of real time continuous glucose monitoring or flash glucose monitoring in the management of diabetes: A consensus view of Italian diabetes experts using the Delphi method.

Bruttomesso D, Laviola L, Avogaro A, Bonora E, Del Prato S, Frontoni S, Orsi E, Rabbone I, Sesti G, Purrello F; of the Italian Diabetes Society (SID).

Nutr Metab Cardiovasc Dis. 2019 May;29(5):421-431. doi: 10.1016/j.numecd.2019.01.018. Epub 2019 Feb 10.

19.

Rational combination therapy for type 2 diabetes.

Del Prato S.

Lancet Diabetes Endocrinol. 2019 May;7(5):328-329. doi: 10.1016/S2213-8587(19)30069-5. Epub 2019 Mar 1. No abstract available.

PMID:
30833171
20.

Factors influencing safe glucose-lowering in older adults with type 2 diabetes: A PeRsOn-centred ApproaCh To IndiVidualisEd (PROACTIVE) Glycemic Goals for older people: A position statement of Primary Care Diabetes Europe.

Hambling CE, Khunti K, Cos X, Wens J, Martinez L, Topsever P, Del Prato S, Sinclair A, Schernthaner G, Rutten G, Seidu S.

Prim Care Diabetes. 2019 Aug;13(4):330-352. doi: 10.1016/j.pcd.2018.12.005. Epub 2019 Feb 18.

PMID:
30792156
21.

Immune Checkpoint Blockade Anti-PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome.

Lanzolla G, Coppelli A, Cosottini M, Del Prato S, Marcocci C, Lupi I.

J Endocr Soc. 2019 Jan 8;3(2):496-503. doi: 10.1210/js.2018-00366. eCollection 2019 Feb 1.

22.

Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes.

Matthews DR, Paldánius PM, Proot P, Foley JE, Stumvoll M, Del Prato S.

Diabet Med. 2019 Apr;36(4):505-513. doi: 10.1111/dme.13886. Epub 2019 Feb 12.

23.

Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.

Handelsman Y, Mathieu C, Del Prato S, Johnsson E, Kurlyandskaya R, Iqbal N, Garcia-Sanchez R, Rosenstock J.

Diabetes Obes Metab. 2018 Nov 30. doi: 10.1111/dom.13594. [Epub ahead of print]

24.

Freestyle Libre trend arrows for the management of adults with insulin-treated diabetes: A practical approach.

Bianchi C, Aragona M, Rodia C, Baronti W, de Gennaro G, Bertolotto A, Del Prato S.

J Diabetes Complications. 2019 Jan;33(1):6-12. doi: 10.1016/j.jdiacomp.2018.10.012. Epub 2018 Oct 24. Review.

PMID:
30446477
25.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S; Harmony Outcomes committees and investigators.

Lancet. 2018 Oct 27;392(10157):1519-1529. doi: 10.1016/S0140-6736(18)32261-X. Epub 2018 Oct 2.

PMID:
30291013
26.

Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour post-load plasma glucose ≥ 155 mg/dl (8.6 mmol/L).

Bergman M, Manco M, Sesti G, Dankner R, Pareek M, Jagannathan R, Chetrit A, Abdul-Ghani M, Buysschaert M, Olsen MH, Nilsson PM, Medina JL, Roth J, Groop L, Del Prato S, Raz I, Ceriello A.

Diabetes Res Clin Pract. 2018 Dec;146:18-33. doi: 10.1016/j.diabres.2018.09.017. Epub 2018 Sep 28. Review.

PMID:
30273707
27.

Pre-pregnancy obesity, gestational diabetes or gestational weight gain: Which is the strongest predictor of pregnancy outcomes?

Bianchi C, de Gennaro G, Romano M, Aragona M, Battini L, Del Prato S, Bertolotto A.

Diabetes Res Clin Pract. 2018 Oct;144:286-293. doi: 10.1016/j.diabres.2018.08.019. Epub 2018 Sep 4.

PMID:
30189224
28.

Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.

Fadini GP, Solini A, Manca ML, Penno G, Gatti A, Anichini R, Del Prato S, Avogaro A; DARWIN-T2D Network.

Diabetes Obes Metab. 2019 Feb;21(2):252-260. doi: 10.1111/dom.13508. Epub 2018 Sep 21.

29.

Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial.

Taskinen MR, Del Prato S, Bujas-Bobanovic M, Louie MJ, Letierce A, Thompson D, Colhoun HM.

Atherosclerosis. 2018 Sep;276:124-130. doi: 10.1016/j.atherosclerosis.2018.07.017. Epub 2018 Jul 21.

30.

Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics.

Green JB, Hernandez AF, D'Agostino RB, Granger CB, Janmohamed S, Jones NP, Leiter LA, Noronha D, Russell R, Sigmon K, Del Prato S, McMurray JJV.

Am Heart J. 2018 Sep;203:30-38. doi: 10.1016/j.ahj.2018.03.030. Epub 2018 Jun 12.

PMID:
30015066
31.

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.

Fioretto P, Del Prato S, Buse JB, Goldenberg R, Giorgino F, Reyner D, Langkilde AM, Sjöström CD, Sartipy P; DERIVE Study Investigators.

Diabetes Obes Metab. 2018 Nov;20(11):2532-2540. doi: 10.1111/dom.13413. Epub 2018 Jul 10. Erratum in: Diabetes Obes Metab. 2019 Jan;21(1):203.

32.

Influence of high density lipoprotein cholesterol levels on circulating monocytic angiogenic cells functions in individuals with type 2 diabetes mellitus.

Lucchesi D, Popa SG, Sancho V, Giusti L, Garofolo M, Daniele G, Pucci L, Miccoli R, Penno G, Del Prato S.

Cardiovasc Diabetol. 2018 Jun 5;17(1):78. doi: 10.1186/s12933-018-0720-1.

33.

Albuminuric and non-albuminuric chronic kidney disease in type 1 diabetes: Association with major vascular outcomes risk and all-cause mortality.

Garofolo M, Russo E, Miccoli R, Lucchesi D, Giusti L, Sancho-Bornez V, Daniele G, Del Prato S, Penno G.

J Diabetes Complications. 2018 Jun;32(6):550-557. doi: 10.1016/j.jdiacomp.2018.03.012. Epub 2018 Apr 3.

PMID:
29705091
34.

Ten Years of Vildagliptin.

Del Prato S.

Eur Endocrinol. 2017 Aug;13(2):54-55. doi: 10.17925/EE.2017.13.02.54. Epub 2017 Aug 22.

35.

Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.

Mathieu C, Del Prato S, Botros FT, Thieu VT, Pavo I, Jia N, Haupt A, Karanikas CA, García-Pérez LE.

Diabetes Obes Metab. 2018 Aug;20(8):2023-2028. doi: 10.1111/dom.13313. Epub 2018 May 2.

36.

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin.

Del Prato S, Rosenstock J, Garcia-Sanchez R, Iqbal N, Hansen L, Johnsson E, Chen H, Mathieu C.

Diabetes Obes Metab. 2018 Jun;20(6):1542-1546. doi: 10.1111/dom.13258. Epub 2018 Mar 25.

37.

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.

Ray KK, Leiter LA, Müller-Wieland D, Cariou B, Colhoun HM, Henry RR, Tinahones FJ, Bujas-Bobanovic M, Domenger C, Letierce A, Samuel R, Del Prato S.

Diabetes Obes Metab. 2018 Jun;20(6):1479-1489. doi: 10.1111/dom.13257. Epub 2018 Mar 23.

38.

Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors.

Del Prato S, Chilton R.

Diabetes Obes Metab. 2018 Apr;20(4):786-799. doi: 10.1111/dom.13169. Epub 2017 Dec 21. Review.

39.

Metabolic regulation of GLP-1 and PC1/3 in pancreatic α-cell line.

Sancho V, Daniele G, Lucchesi D, Lupi R, Ciccarone A, Penno G, Bianchi C, Dardano A, Miccoli R, Del Prato S.

PLoS One. 2017 Nov 9;12(11):e0187836. doi: 10.1371/journal.pone.0187836. eCollection 2017.

40.

Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial.

Ma RC, Del Prato S, Gallwitz B, Shivane VK, Lewis-D'Agostino D, Bailes Z, Patel S, Lee J, von Eynatten M, Di Domenico M, Ross SA.

J Diabetes Investig. 2017 Sep 16. doi: 10.1111/jdi.12746. [Epub ahead of print]

41.

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.

Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; Italian Diabetes Society.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):887-897. doi: 10.1016/S2213-8587(17)30317-0. Epub 2017 Sep 13. Erratum in: Lancet Diabetes Endocrinol. 2017 Nov;5(11):e7.

PMID:
28917544
42.

Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.

Leiter LA, Cariou B, Müller-Wieland D, Colhoun HM, Del Prato S, Tinahones FJ, Ray KK, Bujas-Bobanovic M, Domenger C, Mandel J, Samuel R, Henry RR.

Diabetes Obes Metab. 2017 Dec;19(12):1781-1792. doi: 10.1111/dom.13114. Epub 2017 Oct 10.

43.

Erratum. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 2017;40:813-820.

Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ.

Diabetes Care. 2017 Nov;40(11):1606. doi: 10.2337/dc17-er11. Epub 2017 Sep 8. No abstract available.

44.

Is a motivational interviewing based lifestyle intervention for obese pregnant women across Europe implemented as planned? Process evaluation of the DALI study.

Jelsma JGM, Simmons D, Gobat N, Rollnick S, Blumska K, Jans G, Galjaard S, Desoye G, Corcoy R, Juarez F, Kautzky-Willer A, Harreiter J, van Assche A, Devlieger R, Timmerman D, Hill D, Damm P, Mathiesen ER, Wender-Ożegowska E, Zawiejska A, Lapolla A, Dalfrà MG, Del Prato S, Bertolotto A, Dunne F, Jensen DM, Andersen L, Snoek FJ, van Poppel MNM.

BMC Pregnancy Childbirth. 2017 Sep 7;17(1):293. doi: 10.1186/s12884-017-1471-9.

45.

Normoalbuminuric chronic kidney disease in type 1 diabetes: is it real and is it serious? Reply to Rigalleau V, Blanco L, Alexandre L et al [letter].

Penno G, Russo E, Garofolo M, Daniele G, Lucchesi D, Giusti L, Sancho Bornez V, Bianchi C, Dardano A, Miccoli R, Del Prato S.

Diabetologia. 2017 Oct;60(10):2123-2125. doi: 10.1007/s00125-017-4387-z. Epub 2017 Aug 2. No abstract available.

PMID:
28770329
46.

Italian national guidelines for the screening of gestational diabetes: Time for a critical appraisal?

Bianchi C, de Gennaro G, Romano M, Battini L, Aragona M, Corfini M, Del Prato S, Bertolotto A.

Nutr Metab Cardiovasc Dis. 2017 Aug;27(8):717-722. doi: 10.1016/j.numecd.2017.06.010. Epub 2017 Jun 23.

PMID:
28755805
47.

Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?

Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder REJ.

Diabetes Care. 2017 Jul;40(7):813-820. doi: 10.2337/dc16-2736. Erratum in: Diabetes Care. 2017 Sep 8;:.

48.

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.

Müller-Wieland D, Leiter LA, Cariou B, Letierce A, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M.

Cardiovasc Diabetol. 2017 May 25;16(1):70. doi: 10.1186/s12933-017-0552-4.

49.

A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.

Avogaro A, Giaccari A, Fioretto P, Genovese S, Purrello F, Giorgino F, Del Prato S.

Expert Rev Clin Pharmacol. 2017 Jul;10(7):763-772. doi: 10.1080/17512433.2017.1322507. Epub 2017 May 2. Review.

PMID:
28431476
50.

A Fermented Whole Grain Prevents Lipopolysaccharides-Induced Dysfunction in Human Endothelial Progenitor Cells.

Giusti L, Gabriele M, Penno G, Garofolo M, Longo V, Del Prato S, Lucchesi D, Pucci L.

Oxid Med Cell Longev. 2017;2017:1026268. doi: 10.1155/2017/1026268. Epub 2017 Mar 13.

Supplemental Content

Loading ...
Support Center